Polyphor is a clinical stage, privately held Swiss specialty Pharma Company, focused on the develop­ment of macrocycle drugs that address antibiotic resistance and severe respiratory diseases. The com­pany's lead drug candidates include: 

• Murepavadin (POL7080, entering Phase III / pivotal registration program), a precision Outer Membrane Protein Targeting Antibiotic (OMPTA) against Pseudomonas aeruginosa.
   
• POL6014 (in Phase Ib), an inhaled inhibitor of neutrophil elastase for the treatment of cystic fibrosis and other neutrophilic lung diseases.
   
• Balixafortide (POL6326, in Phase Ib), an antagonist of the chemokine receptor CXCR4 for combination treatment in oncology.

In addition, Polyphor has discovered and is developing the OMPTA class to address infections caused by difficult-to-treat, resistant Gram-negative pathogens. Polyphor has an important activity of discovery technology partnerships to assist pharma companies in research programs addressing difficult targets through its proprietary macrocycle technology platform.